BRIEF published on 02/28/2024 at 14:00, 2 years 6 months ago Galimedix Therapeutics Presents New Preclinical Data on GAL-201 at AD/PD™ 2024 Conference Alzheimer's Disease GAL-201 AD/PD™ 2024 Galimedix Therapeutics Preclinical
BRIEF published on 02/28/2024 at 14:00, 2 years 6 months ago Galimedix Therapeutics présente de nouvelles données précliniques sur le GAL-201 lors de la conférence AD/PD™ 2024 GAL-201 Maladie D'Alzheimer Préclinique AD/PD™ 2024 Galimedix Therapeutics
PRESS RELEASE published on 10/25/2023 at 14:00, 2 years 10 months ago Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations
Published on 09/11/2026 at 04:00, 3 hours 23 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 8 hours 58 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 16 hours 3 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 16 hours 23 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 00:05, 7 hours 18 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 7 hours 22 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 8 hours 44 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 9 hours 13 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 9 hours 16 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/11/2026 at 07:00, 23 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 23 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 11 hours 53 minutes ago Availability of the 2026 Interim Financial Report
